# Gemcitabine Hydrochloride, Cisplatin, Nab-Paclitaxel, and Durvalumab in Treating Patients With Locally Advanced or Metastatic Gallbladder Cancer

> **NCT06591650** · PHASE2 · RECRUITING · sponsor: **Fudan University** · enrollment: 33 (estimated)

## Conditions studied

- Gallbladder Cancer Unresectable

## Interventions

- **DRUG:** gemcitabine hydrochloride
- **DRUG:** Cisplatin
- **DRUG:** Nab-paclitaxel
- **DRUG:** Durvalumab

## Key facts

- **NCT ID:** NCT06591650
- **Lead sponsor:** Fudan University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-10-24
- **Primary completion:** 2026-10-30
- **Final completion:** 2027-10-30
- **Target enrollment:** 33 (ESTIMATED)
- **Last updated:** 2026-05-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06591650

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06591650, "Gemcitabine Hydrochloride, Cisplatin, Nab-Paclitaxel, and Durvalumab in Treating Patients With Locally Advanced or Metastatic Gallbladder Cancer". Retrieved via MORVS 2026-10-17 from https://api.morvs.ai/clinical/NCT06591650. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*